PATENT CLAIM ANALYSIS

Application Number: 16016250
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "279000"]

Abstract:
The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Claim (Index 25):
The method of  claim 20 , wherein the first buprenorphine composition and the third buprenorphine composition comprise: (i) about 300 mg buprenorphine free base at about 14 wt % to about 22 wt %; (ii) about 22 wt % to about 42 wt % of a 50:50 to 80:20 poly(DL-lactide-co-glycolide) copolymer having a weight average molecular weight of about 5,000 Daltons to about 30,000 Daltons; and (iii) about 40 wt % to about 60 wt % of N-methyl-2-pyrrolidone; and wherein the second buprenorphine composition comprises: (i) about 100 mg buprenorphine free base at about 10 wt % to about 30 wt %; (ii) about 10 wt % to about 60 wt % of a 50:50 to 95:5 poly(DL-lactide-co-glycolide) copolymer having a weight average molecular weight of about 5,000 Daltons to about 40,000 Daltons; and (iii) about 30 wt % to about 70 wt % of N-methyl-2-pyrrolidone.

Metadata:
- Claim Count in Document: 110.0
- Percentile: 94.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15623191', '13836134', '15857507', '14610818', '15334000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8049699534572636
- 35 USC 102 Novelty (BERT): 0.5208497418945603
- Combined Prediction Score: 0.7765579323009933
- Mean Citation Score: 302.2236400000001
- Max Citation Score: 315.9235
- Similarity Product: 250.8223099845349

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test